Sugi Predict

Sugi Predict / Compounds / SCHEMBL2216616

SCHEMBL2216616

SCHEMBL2216616

Cc1cc(=O)oc2c(F)c(O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)c(F)cc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 6/20 0.58
▸ CA9 Q16790 6/20 0.58
▸ CA1 P00915 5/20 0.58
▸ CA2 P00918 2/20 0.58
▸ KMT2A Q03164 3/20 0.52
▸ CA7 P43166 2/20 0.50
▸ CA13 Q8N1Q1 2/20 0.50
▸ MEN1 O00255 2/20 0.49
▸ ALDH1A1 P00352 3/20 0.47
▸ EPHX2 P34913 1/20 0.47
▸ SOST Q9BQB4 1/20 0.44
▸ POLB P06746 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ CASP1 P29466 2/20 0.42
▸ CASP7 P55210 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ GLA P06280 1/20 0.42
▸ GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL381305 1.00 CA12 (0.58) CA12CA9CA1CA2KMT2A
SCHEMBL22078960 1.00 CA12 (0.58) CA12CA9CA1CA2KMT2A
SCHEMBL30434987 1.00 CA12 (0.58) CA12CA9CA1CA2KMT2A
SCHEMBL2287566 1.00 CA12 (0.58) CA12CA9CA1CA2KMT2A
SCHEMBL8570406 1.00 CA12 (0.58) CA12CA9CA1CA2KMT2A
SCHEMBL24426595 1.00 CA12 (0.58) CA12CA9CA1CA2KMT2A
SCHEMBL26356083 0.86 KMT2A (0.62) CA12CA9CA1CA2KMT2A
SCHEMBL16098409 0.86 KMT2A (0.50) CA12CA9CA1CA2KMT2A
SCHEMBL3074305 0.86 KMT2A (0.50) CA12CA9CA1CA2KMT2A
SCHEMBL23479723 0.85 KMT2A (0.55) CA12CA9CA1CA2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9701968-B2 Biological indicator AMERICAN STERILIZER COMPANY (US) 2017-07-11 — — US claimed
US-20160312263-A1 BIOLOGICAL INDICATOR AMERICAN STERILIZER CO (US) 2016-10-27 — — US claimed
US-20160102335-A1 BIOLOGICAL INDICATOR AMERICAN STERILIZER COMPANY 2016-04-14 — — US claimed
US-8895239-B2 Genetically engineered biological indicator AMERICAN STERILIZER COMPANY (US) 2014-11-25 — — US claimed
EP-2084293-B1 GENETICALLY ENGINEERED BIOLOGICAL INDICATOR AMERICAN STERILIZER CO (US) 2014-08-13 — — EP claimed
US-8507248-B2 Genetically engineered biological indicator AMERICAN STERILIZER COMPANY (US) 2013-08-13 — — US claimed
US-20100267044-A1 GENETICALLY ENGINEERED BIOLOGICAL INDICATOR FRANCISKOVICH PHILLIP P 2010-10-21 — — US claimed
US-20080070231-A1 Reporter genes taken up by microorganism, and repressor gene inhibits expression AMERICAN STERILIZER COMPANY 2008-03-20 — — US claimed
EP-1704244-A2 METHODS, COMPOSITIONS, AND KITS FOR ANALYSIS OF ENZYME ACTIVITY IN CELLS Applera Corporation, Applied Biosystems Group (US) 2006-09-27 — — EP claimed
US-20050244907-A1 Methods, compositions, and kits for analysis of enzyme activity in cells APPLERA CORPORATION 2005-11-03 — — US claimed
WO-2005059163-A2 METHODS, COMPOSITIONS, AND KITS FOR ANALYSIS OF ENZYME ACTIVITY IN CELLS APPLERA CORPORATION (US) 2005-06-30 — — WO claimed
US-11976110-B2 Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells MERZ PHARMA GMBH & CO. KGAA (DE) 2024-05-07 — — US disclosed
US-20230313261-A1 Biological Indicator Comprising Genetically-Modified Test Microorganism SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2023-10-05 — — US disclosed
US-11773127-B2 Compounds and methods for treating bacterial infections WASHINGTON UNIVERSITY (US) 2023-10-03 — — US disclosed
US-11773127-B2 Compounds and methods for treating bacterial infections WASHINGTON UNIVERSITY (US) 2023-10-03 — — US disclosed
US-6548632-B1 Green fluorescent protein to increase the cellular expression levels, conformational stability relative to linear peptides, and the steady state concentrations of random peptides and decrease cellular catabolism RIGEL PHARMACEUTICALS, INC. 2003-04-15 — — US disclosed
US-6548249-B1 First, second and a third nucleic acids encoding a Renilla GFP scaffold protein, a different random peptide fused to N-terminus of scaffold protein, and a flexible linker between scaffold and random peptide accordingly, screening the cells RIGEL PHARMACEUTICALS, INC. 2003-04-15 — — US disclosed
EP-1119617-A2 FUSIONS OF SCAFFOLD PROTEINS WITH RANDOM PEPTIDE LIBRARIES Rigel Pharmaceuticals, Inc. (US) 2001-08-01 — — EP disclosed
WO-2000020574-A9 FUSIONS OF SCAFFOLD PROTEINS WITH RANDOM PEPTIDE LIBRARIES RIGEL PHARMACEUTICALS INC (US) 2001-06-21 — — WO disclosed
WO-2000020574-A2 FUSIONS OF SCAFFOLD PROTEINS WITH RANDOM PEPTIDE LIBRARIES RIGEL PHARMACEUTICALS, INC. (US) 2000-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773127-B2 Compounds and methods for treating bacterial infections MMP8, ELANE, MPO CA12 420/4885CA9 204/4885CA1 1677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.